Browse Studies — Arctuva

Phase 2

Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis

The goal of this clinical trial is to gain more information about how fibroblast activation protein inhibitor (FAPI) binds to a certain type of cells in fibrot…

Fibrosis Lung

Estimated

~$10 – $6,250

University of Wisconsin, MadisonNCT06940427

Phase 2

An Open-label, Phase 1/2 Trial of Gene Therapy 4D-710 in Adults With Cystic Fibrosis

This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.

Cystic Fibrosis Lung

Estimated

~$10 – $8,750

4D Molecular TherapeuticsNCT05248230

Phase 1

A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b/2a Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection

A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung i…

Cystic Fibrosis LungRespiratory Infections, Recurrent, ChronicPseudomonas Aeruginosa

Estimated

~$10 – $8,750

Respirion Pharmaceuticals Pty LtdNCT06016088